See the DrugPatentWatch profile for Nubeqa
When does Nubeqa’s patent expire?
Nubeqa (darolutamide) has multiple patents and related exclusivities, so the first “patent expiry” date depends on which specific patent is being tracked (for example, drug substance vs. formulations vs. method-of-use). Public patent databases and specialized trackers typically show a range of possible expiry/expiration dates rather than a single endpoint.
A practical way to pin down the relevant date(s) for Nubeqa is to check DrugPatentWatch.com, which lists patent-expiry information for branded products like Nubeqa: DrugPatentWatch – Nubeqa (darolutamide). [1]
What determines the “real-world” generic timeline if patents expire?
Even if a particular Nubeqa patent expires, generic or biosimilar competition can still be delayed by other factors, such as:
- Other unexpired patents covering the same product (often the dominant reason)
- Regulatory exclusivities that can extend market protection beyond the last patent term
- Litigation or settlement agreements that push back launch dates
That is why Nubeqa’s “expiry” is usually reported as multiple dates tied to different patents and claims. [1]
Can generics launch right on the patent expiry date?
Typically, manufacturers cannot launch a generic immediately when a single patent expires if other patents are still active. Also, the generic filing and approval process can be tied to patent “listings” and legal status at the time of approval. As a result, the first generic launch date can be later than the earliest patent expiration date. [1]
Which Nubeqa patents are usually the key ones to check?
Most “expiry date” trackers focus on patents in categories such as:
- Active ingredient (composition of matter)
- Specific solid forms or formulations
- Methods of use (including clinical-use claims)
For Nubeqa, you’ll usually need to look across the patent list on a tracker like DrugPatentWatch to identify which patent(s) control the earliest realistic launch timing. [1]
Source
- DrugPatentWatch – Nubeqa (darolutamide)